Making sense of GLP-1 agonists
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents… read more.
GLP-1 receptor agonists (GLP-1RAs) such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents… read more.
Pfizer Inc. announced that the European Commission (EC) has granted marketing authorization for Litfulo (ritlecitinib) to treat adults and adolescents 12 years of age and older with severe… read more.
The work of a consultant pharmacist in diabetes spans clinical duties and leadership tasks including education and mentoring. There are at present only three consultant pharmacists in diabetes… read more.
In the future, GLP-1 agonists could be used early in treatment for type II diabetes and this could have an important impact on slowing the onset of complications,… read more.
The FDA has accepted for review a biologics license application (BLA) seeking the approval of tislelizumab (Tevimbra) for use in the frontline treatment of patients with unresectable, recurrent,… read more.
Researchers aimed to identify factors leading primary care practice personnel to decline participation in quality improvement (QI) projects, and strategies to improve the feasibility and attractiveness of QI… read more.
GLP-1 agonists such as semaglutide were developed for treatment of type II diabetes but have also been successful as weight-loss agents for non-diabetics. Many new agents are now… read more.
Members of the University of Ottawa Department of Family Medicine conducted a scoping review to understand men’s communication preferences when they discuss prostate cancer screening with their doctors…. read more.
Clinical researchers at the University of Minnesota Medical School partnered with the university health system’s compliance department to create standard processes for ordering and documenting mifepristone administration, which… read more.
Merck Inc., known as MSD outside of the United States and Canada, announced the FDA has accepted for priority review a new supplemental Biologics License Application (sBLA) seeking… read more.
Aging has been identified as a significant risk factor for herpes zoster, a skin disease caused by the same virus that causes chickenpox. With the aging of the… read more.
Individuals with opioid use disorder who were prescribed a lower buprenorphine dose were 20% more likely to discontinue treatment than those on a higher dose, according to a… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.